CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 (ALK1) receptor, slows tumor growth and progression by inhibiting angiogenesis. The paper titled “Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis” was published in the Journal of Experimental Medicine in collaboration with researchers from the Karolinska Institute in Sweden. A second paper, titled “ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth,” was published in Molecular Cancer Therapeutics by researchers at Acceleron.
